| DEFINIUM THERAPEUTICS |
| Kanada |
| Gesundheit |
| CA24477V1058 / A420P3 |
| MMQ0 (Frankfurt) / DFTX (NASDAQ) |
| FRA:MMQ0, ETR:MMQ0, MMQ0:GR, NASDAQ:DFTX |
| - |
| https://definiumtx.com/ |
|
Definium Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in New York, specializing in the development of psychedelic-derived therapeutics for psychiatric and neurological disorders. Formerly known as MindMed, it focuses..
>Volltext.. |
| 1922.07 Mio. EUR |
| 1605.81 Mio. EUR |
| - |
| -141.37 Mio. EUR |
| -156.23 Mio. EUR |
| -1.76 EUR |
| 34.49 Mio. EUR |
| 219.17 Mio. EUR |
| -112.07 Mio. EUR |
| 6.17 |
| - |
| -49.06% |
| - |
| - |
| - |
| DEFINIUM |
| 21.04.26 |
|